Novartis AG ADR (NVS)vsQ32 Bio Inc (QTTB)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
QTTB
Q32 Bio Inc
$5.60
+1.82%
HEALTHCARE · Cap: $83.68M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 105187% more annual revenue ($56.58B vs $53.74M). QTTB leads profitability with a 55.5% profit margin vs 23.9%. QTTB trades at a lower P/E of 2.4x. QTTB earns a higher WallStSmart Score of 62/100 (C+).
NVS
Buy51
out of 100
Grade: C-
QTTB
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Intrinsic value data unavailable for QTTB.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Attractively priced relative to earnings
Every $100 of equity generates 125 in profit
Keeps 56 of every $100 in revenue as profit
Strong operational efficiency at 85.4%
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : QTTB
The strongest argument for QTTB centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 55.5% and operating margin at 85.4%.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : QTTB
The primary concerns for QTTB are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
NVS profiles as a declining stock while QTTB is a value play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.52 — expect wider price swings.
QTTB is growing revenue faster at 0.0% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
QTTB scores higher overall (62/100 vs 51/100), backed by strong 55.5% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Q32 Bio Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Q32 Bio Inc. (QTTB) is an innovative biotechnology company specializing in the development of cutting-edge antibody-based therapies aimed at treating autoimmune diseases and optimizing immune responses. With its proprietary technology platform, Q32 Bio is advancing a diverse pipeline of therapeutic candidates poised to restore immune balance and address critical unmet medical needs. Supported by a highly experienced management team and strategic partnerships, Q32 Bio is strategically positioned to drive meaningful advancements in healthcare, ultimately creating long-term value for shareholders through its commitment to ongoing research and development excellence.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?